Strut: What the FDA Letter Means for What You Pay

This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://www.struthealth.com, in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.

1. 1

   “The compounded semaglutide and tirzepatide products displayed on your website identify "Strut" on the pictured label, suggesting Strut is the compounder of those drugs when in fact it is not.”

2. 2

   “Additionally, the following claims concerning compounded semaglutide and tirzepatide products appear on your website: "Generic Zepbound, Mounjaro" "Semaglutide is the active ingredient in the brand medications." "Tirzepatide is the active ingredient in the brand medications Zepbound® and Mounjaro®."”

3. 3

   “Compounded drug products are not FDA-approved. Your claims imply that your products have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not.”

1. 1

   Letter issued

   February 2026

2. 2

   15-working-day response window

   FDA gives the company 15 working days to respond in writing.

3. 3

   Close-out, if issued

   FDA may post one once it is satisfied the cited issues have been corrected.

struthealth.com returned a live storefront when we checked in August 2026, still operating under the Strut name.

Calling a compounded product "Generic Zepbound, Mounjaro" is the most direct brand-substitution language in this dataset — "generic" is a specific FDA-regulated term for an approved, interchangeable copy of a brand drug, which a compounded product is not. That word choice, not the medication itself, is what FDA objected to; it doesn't tell you whether Strut's price or care model is good, only that this specific comparison overstated what FDA has approved.

Doseworth’s review of Strut has the pricing, the states served, and what’s included.

As of August 2026, FDA’s public tracking for this letter does not show a logged company response. Companies are not required to make a response public, and FDA does not always update this field promptly — this is not evidence Strut failed to respond.